Provided by Tiger Trade Technology Pte. Ltd.

Quidel

29.39
+0.51001.77%
Pre-market: 29.420.0300+0.10%04:31 EST
Volume:789.97K
Turnover:23.15M
Market Cap:2.00B
PE:-1.68
High:29.51
Open:28.80
Low:28.69
Close:28.88
52wk High:49.45
52wk Low:19.50
Shares:67.93M
Float Shares:62.65M
Volume Ratio:0.74
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.4448
EPS(LYR):-30.5357
ROE:-45.16%
ROA:1.42%
PB:0.98
PE(LYR):-0.96

Loading ...

QuidelOrtho Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Wins and Margin Expansion

Earnings Call
·
Nov 06

Stock Track | Quidel Soars 5.96% After Hours on Strong Q3 Results and Upbeat Outlook

Stock Track
·
Nov 06

Stock Track | QuidelOrtho Soars 5.96% After-Hours on Strong Q3 Results and Positive Outlook

Stock Track
·
Nov 06

QuidelOrtho (QDEL) Q3 2025 Earnings Transcript

Motley Fool Transcribing
·
Nov 06

In vitro diagnostics firm QuidelOrtho beats Q3 revenue expectations

Reuters
·
Nov 06

QuidelOrtho reports third quarter revenue of $700 million and adjusted diluted EPS of $0.80

Reuters
·
Nov 06

BRIEF-QuidelOrtho Q3 EPS USD -10.78

Reuters
·
Nov 06

QuidelOrtho Outlook FY Adjusted EPS USD 2-2.15

THOMSON REUTERS
·
Nov 06

QuidelOrtho (QDEL) Gets a Buy from Craig-Hallum

TIPRANKS
·
Nov 04

BRIEF-QuidelOrtho Receives FDA 510(k) Clearance for VITROS Immunodiagnostic Products hs Troponin I Assay

Reuters
·
Nov 03

QuidelOrtho Wins FDA Clearance for VITROS High-Sensitivity Troponin I Assay

Reuters
·
Nov 03

QuidelOrtho Corp - Commercial Rollout for U.S. Laboratories Operating Vitros Systems to Begin Later This Year

THOMSON REUTERS
·
Nov 03

QuidelOrtho Receives FDA 510(K) Clearance for Vitros™ Immunodiagnostic Products Hs Troponin I Assay

THOMSON REUTERS
·
Nov 03

Evaluating QuidelOrtho (QDEL): Is There Value After the Recent Share Price Rebound?

Simply Wall St.
·
Oct 25

QuidelOrtho Highlights Informatics Advances in Science Bytes Podcast

Reuters
·
Oct 24

QuidelOrtho Corporation to Announce Third Quarter 2025 Financial Results

Reuters
·
Oct 22

QuidelOrtho (QDEL) Valuation in Focus After FDA Nod for Transfusion Medicine Innovation

Simply Wall St.
·
Oct 17

Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40

MT Newswires Live
·
Oct 07

QuidelOrtho Cut to Neutral From Buy by Citigroup

Dow Jones
·
Oct 07

QuidelOrtho Corp : Citigroup Cuts to Neutral From Buy; Cuts Target Price to $33 From $40

THOMSON REUTERS
·
Oct 07